Report: Future Drugmakers Must also Deliver Healthy Outcomes

Biotechs Find Market Success with Alternative Strategies

Will Congress Enact FOBS? Panelists Say It's a Must-Do

Gene Panel Recommendations Called a Patent 'Slippery Slope'

Myriad Ruling Could Have Broad Biotech Implications

Auxilium 'Finally' Wins Xiaflex Approval for Rare Hand Disease

Onyx, FDA Agree on Carfilzomib Multiple Myeloma Trial Design

Biomedical Gets a Boost in Obama FY2011 Budget

White House, Congress Get 'F' for Bioterrorism Preparedness

Government Work 'Easy Money'? Don't Bet Your R&D Budget on it